• 1
    Carter BS, Bova GS, Beatty TH et al. Hereditary prostate cancer: Epidemiology and hereditary. J Urol 1993; 150: 797802.
  • 2
    Umbas R, Isaacs WB, Bringuier PP et al. Decreased e-cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res 1994; 54: 392933.
  • 3
    Lee WH, Morton RA, Epstein JI, Nelson WG. Cytidine methylation of regulatory sequences near the rc-class glutathione-S-transferase gene accompanies human prostate carcinogenesis. Proc Natl Acad Sci USA 1994; 91: 117337.
  • 4
    Hakimi JM, Rondinelli RH, Schoenberg MP, Barrack ER. Androgen receptor gene structure and function in prostate cancer. World J Urol 1996; in press.
  • 5
    Sommerfeld HJ, Meeker AK, Piatyszek MA, Bova GS, Shay JW, Coffey DS. Telomerase activity: A prevalent marker of malignant human prostate tissue. Cancer Res 1996; 56: 218.
  • 6
    Getzenberg RH, Pienta KJ, Ward WS, Coffey DS. Nuclear structure and three-dimensional organization of DNA. J Cell Biochem 1991; 47: 28999.
  • 7
    Partin AW, Getzenberg RH, Carmichael MJ et al. Nuclear matrix proteins in human benign prostatic hyperplasia and prostate cancer. Cancer Res 1993; 53: 1446.
  • 8
    Ellington AD, Szostak JW. In vitro selection of RNA molecules that bind specific ligands. Nature 1990; 346: 81822.
  • 9
    Tuerk C, Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 1990; 249: 50510.
  • 10
    Griffin LC, Tidmarsh GF, Bock LC, Toole JJ, Leung LLK. In vivo anticoagulant properties of a novel nucleotide-based thrombin inhibitor and demonstration of regional anticoagulation in extracorporeal circuits. Blood 1993; 81: 32716.